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Abstract
Heterozygous mutations in p63 are associated with split hand/foot malformations (SHFM), orofacial clefting, and ectodermal
abnormalities. Elucidation of the p63 gene network that includes target genes and regulatory elements may reveal new
genes for other malformation disorders. We performed genome-wide DNA–binding profiling by chromatin immunopre-
cipitation (ChIP), followed by deep sequencing (ChIP–seq) in primary human keratinocytes, and identified potential target
genes and regulatory elements controlled by p63. We show that p63 binds to an enhancer element in the SHFM1 locus on
chromosome 7q and that this element controls expression of DLX6 and possibly DLX5, both of which are important for limb
development. A unique micro-deletion including this enhancer element, but not the DLX5/DLX6 genes, was identified in a
patient with SHFM. Our study strongly indicates disruption of a non-coding cis-regulatory element located more than
250 kb from the DLX5/DLX6 genes as a novel disease mechanism in SHFM1. These data provide a proof-of-concept that the
catalogue of p63 binding sites identified in this study may be of relevance to the studies of SHFM and other congenital
malformations that resemble the p63-associated phenotypes.
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Introduction
The p63 protein encoded by the TP63 gene is a transcription
factor of the p53 family and functions as a master regulator of
ectodermal development. The key function of p63 during
ectodermal development is underscored by phenotypic features
in p63 knockout mice [1,2] and in p63 knock-down zebrafish [3,4].
The developmental abnormalities in animal models are reminis-
cent of those in p63-associated human disorders. Heterozygous
mutations in p63 give rise to at least seven dominantly inherited
clinical conditions with three major characteristics, ectrodactyly
(also known as split hand/foot malformation, SHFM), orofacial
clefting and ectodermal dysplasia with defects in skin, hair, teeth,
nails and exocrine glands [5,6]. There is a clear genotype-
phenotype correlation in p63-associated disorders [7]. The most
prominent of these disorders is the Ectrodactyly Ectodermal
dysplasia and Cleft lip/palate syndrome (EEC, OMIM 604292)
which combines all of the three phenotypic hallmarks and is
almost invariably caused by missense mutations in the DNA
binding domain of p63. Ankyloblepharon Ectodermal defects Cleft
lip/palate syndrome (AEC, OMIM 106260) is caused by
mutations in the SAM domain of the p63 that is involved in
protein interaction. Nonetheless, mutations of p63 can explain
only a minority of patients with only one of the three cardinal
features, such as in patients with isolated SHFM (,10%) and in
patients with isolated cleft lip/palate (,0.1%) [7]. There remains a
large group of ectodermal dysplasia syndromes with phenotypes
that resemble p63-associated syndromes [8]. The genetic basis of
many of these clinically related conditions, referred to as the p63
phenotype network, is presently unknown.
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There is ample evidence that diseases clustering within such
phenotype networks are caused by mutations in functionally
related genes that constitute a gene network [9–11]. Elucidation of
functional interactions among genes within the p63 gene network,
their encoded proteins and regulatory elements which control
expression of these genes will therefore provide new candidate
genes for genetic disorders from the p63 phenotype network.
Identifying target genes and cis-regulatory elements controlled by
p63 is an important step in dissecting the p63 gene network.
Previous studies have focused on transcriptional target genes of
p63 identified through individual candidate gene approaches [12–
14] or through genome-wide approaches [15–19]. However, the
role of regulatory elements controlled by p63 in transcription has
not yet been addressed so far.
Split hand/split foot malformation (SHFM, OMIM 183600) is
characterized by a deficiency of the central rays of the hands and
feet, resulting in missing or malformed digits. SHFM may be
isolated (non-syndromic) or be associated with other developmen-
tal anomalies (syndromic). Six distinct chromosomal loci for non-
syndromic SHFM have been reported. Specific gene mutations
have been identified in SHFM6 and SHFM4. SHFM6 (OMIM
225300, chromosome 12q13) is caused by a homozygous
WNT10B mutation and it is the only autosomal recessive form
of SHFM [20]. SHFM4 (OMIM 605289, chromosome 3q27) is
caused by p63 mutations [21]. Chromosomal aberrations underlie
three other types of isolated SHFM: 7q21 deletions and re-
arrangements in SHFM1 (OMIM 183600) [22], 10q24 duplica-
tions encompassing the Dactylin gene (FBXW4) in SHFM3 (OMIM
600095) [23], and 2q31 deletions encompassing the HOXD gene
cluster in SHFM5 (OMIM 606708) [24,25]. In addition, linkage
analysis has mapped SHFM2 (OMIM 313350) to chromosome
Xq26 [26].
The SHFM1 locus on chromosome 7q21 has been delineated
by various translocations, inversions, deletions and duplications
[27]. The smallest region of overlapping deletions in SHFM1
patients [28] encompasses several genes: DYNC1I1, SLC25A13,
DSS1, DLX5 and DLX6, of which only DLX5 and DLX6 have been
shown to clearly play a role in early limb development. Dlx5 and
Dlx6 are highly expressed in the apical ectodermal ridge (AER) of
the developing limbs of mice [29–31] and in the fins of zebrafish
[3,4]. The AER is critical for limb outgrowth and patterning [32]
and there is strong evidence that a failure to maintain the AER
signaling is the main pathogenic mechanism in ectrodactyly [33].
The importance of the DLX5/DLX6 genes in limb development
has been highlighted in mouse models. Dlx5 deficient mice do not
show any limb defects [30]. However, an SHFM-like phenotype
has been observed when both Dlx5 and Dlx6 were simultaneously
deleted (Dlx5/Dlx62/2). The limb developmental phenotype in
Dlx5/Dlx62/2 mice could be fully rescued by overexpression of
Dlx5 in the AER [29,34]. These observations suggest that the
DLX5 and DLX6 genes cooperate in limb development by
controlling a common developmental program. DLX5 and DLX6
are further expressed in the craniofacial prominence, the otic
vesicle and in the brain [29–31], which correlates well with the
hearing loss and mental retardation that are present in 30% of the
SHFM1 patients [27]. While DLX5 and DLX6 are obvious
candidate genes for SHFM1, mutations have not been found in
either of the two genes.
Here, we used a genome-wide DNA-binding profiling approach
using Chromatin Immunoprecipitation (ChIP) followed by deep
sequencing (ChIP-seq) in human primary keratinocytes to
generate a catalogue of highly informative target genes and
regulatory elements controlled by p63. One cis-regulatory element
identified by DNA-binding profiling is located in the SHFM1
critical region and acts as an enhancer element for gene expression
mediated by p63 during embryonic limb development. Our data
indicate that loss of this element leads to SHFM1. This example
illustrates that our catalogue of p63 binding sites can identify
candidate genes and loci for the elucidation of disorders from the
p63 phenotype network.
Results
Genome-wide p63 binding profile in human primary
keratinocytes
The most common isoform of p63, DNp63a, is highly expressed
in the basal layer of the epidermis that consists mainly of
keratinocytes. We therefore established human primary keratino-
cyte cultures (HKCs) from adult skin as our model system to
elucidate p63 gene networks under physiological conditions. To
identify target genes and regulatory elements controlled by p63,
high-resolution global binding profiles of p63 were obtained from
HKC cell lines established from two unrelated control individuals
(wt1 and wt2) by ChIP-seq analysis using two antibodies
recognizing different epitopes in p63 (4A4 and H129). Analysis
of the sequenced reads using the peak recognition algorithm of
Model-based Analysis of ChIP-Seq (MACS) [35] gave a highly
significant overlap of 11,369 peaks from three profiles (P,1E-300)
(Figure 1A). Overlapping peaks were therefore considered as a
collection of high-fidelity p63 binding sites in HKCs. Indeed, a set
of 17 representative binding sites of various peak heights,
conservation scores and consensus motif scores (see below) were
tested with independent ChIP followed by qPCR analysis (ChIP-
qPCR) with two antibodies (4A4 and H129) and all of them could
be validated (Table S1, Figure S1). This confirmed that the
obtained p63 binding profile is highly reliable.
To determine the specific p63-binding sequences in the detected
binding sites, a de novo consensus motif prediction pipeline was
applied to generate a Position Weight Matrix (PWM) (see
Materials and Methods for details). A highly significant consensus
sequence was identified that is similar to the previously reported
Author Summary
Mammalian embryonic development requires precise
control of gene expression in the right place at the right
time. One level of control of gene expression is through
cis-regulatory elements controlled by transcription factors.
Deregulation of gene expression by mutations in such cis-
regulatory elements has been described in developmental
disorders. Heterozygous mutations in the transcription
factor p63 are found in patients with limb malformations,
cleft lip/palate, and defects in skin and other epidermal
appendages, through disruption of normal ectodermal
development during embryogenesis. We reasoned that
the identification of target genes and cis-regulatory
elements controlled by p63 would provide candidate
genes for defects arising from abnormally regulated
ectodermal development. To test our hypothesis, we
carried out a genome-wide binding site analysis and
identified a large number of target genes and regulatory
elements regulated by p63. We further showed that one of
these regulatory elements controls expression of DLX6 and
possibly DLX5 in the apical ectodermal ridge in the
developing limbs. Loss of this element through a micro-
deletion was associated with split hand foot malformation
(SHFM1). The list of p63 binding sites provides a resource
for the identification of mutations that cause ectodermal
dysplasias and malformations in humans.
Gene Network of p63 in Developmental Disorders
PLoS Genetics | www.plosgenetics.org 2 August 2010 | Volume 6 | Issue 8 | e1001065
p63 and p53 consensus motifs (P,1E-250) [17,18,36,37]
(Figure 1B, Table S2). An additional significant AP1-like motif
that can be bound by c-Fos and c-Jun proteins [38] was also
identified in the detected binding sites (P,1E-50, Table S2). We
combined our previously developed p53scan algorithm [37] with
the newly identified p63 PWM, hereafter referred to as p63scan.
Comparison of p63scan with the previously described motif
algorithms p63MH [36] and p53scan [37] showed that p63scan
had clearly higher sensitivity for motif recognition without
compromising the specificity (Figure 1C). A slight increase of
motif scores correlated with an increase of peak heights of the
binding sites (Figure S2), suggesting a stronger binding of p63 to
binding sites with higher motif scores. Using p63scan, 10,702 out
of a total 11,369 p63 binding sites (94%) were found to contain at
least one p63 motif (motif score 4.74, False Discovery Rate, FDR
10%). The high percentage of motif-containing binding sites
indicates that most binding sites identified in this study participate
in direct binding of p63. The de novo consensus motif prediction
pipeline was applied to the subgroup of binding sites without p63
binding motifs to search for consensus motifs of other transcription
Figure 1. Characterization of identified p63 binding sites. (A) A screenshot of chromosome 3 using UCSC genome browser shows similar
DNA-binding profiles from our ChIP-seq analysis of two normal human primary keratinocyte cell lines (wt1 and wt2) with two different antibodies
(4A4, pan-p63 and H129, a-specific). The p63 binding sites analyzed with MACS [35] using P value 161029 are shown in red, and previously reported
p63 binding sites in ChIP-on-chip analysis [17] are shown in black. (B) The p63 motif was identified by a de novo motif analysis (see Materials and
Methods). Based on a previously developed p53scan algorithm [37] with this newly identified p63 Positional Weight Matrix (PWM), p63scan was
developed. (C) The performance of p63scan using the de novo identified motif shows superior sensitivity compared to previously reported p63MH
without compromising specificity. (D) Distribution of the p63-binding site location relative to RefSeq genes. Locations of binding sites are divided
into: TSS flanking region (5 kb upstream of TSS, first exon and first intron), intragenic region (all introns and exons except first), ,25 kb (5–25 kb
upstream or 25 kb downstream of last exon), or intergenic regions (everything else). The asterisk represents significant enrichment.
doi:10.1371/journal.pgen.1001065.g001
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factors or novel binding motifs of p63. A degenerate p63 binding
motif was identified, and interestingly, the AP1 motif was also
found more strongly enriched as compared to the motif analysis of
all binding sites (Table S2). An alternative approach also was taken
to examine all known motifs of transcription factors in the
TRANSFAC Professional database (version 2009.3) [39] for their
significant over-representation (P,1E-10, after Bonferroni correc-
tion) in the p63 motif-less binding sites relative to the p63 motif-
containing sites. Consistent with the de novo consensus motif search,
the AP1 motif as well as the BACH1 and BACH2 motifs that are
similar to AP1 was found (Table S3). These data suggest that p63
can bind to DNA by collaborating with other transcription factors
such as c-Jun or c-Fos. Interestingly, a previous report showed that
p63 binds to an AP1 responsive element to regulate Keratin 1 in
keratinocytes in a c-Jun dependent manner [40]. No other novel
consensus binding motifs were detected.
Out of 11,369 binding sites, 1460 lie between 5 kb upstream of the
transcription start site (TSS) and the end of the first intron of genes,
referred to as TSS flanking regions, and 1908 binding sites are located
within 25 kb distance to a gene (,25kb region) (Figure 1D). Statistical
analysis showed that binding sites at these two chromosomal regions
are enriched compared to genomic distributions of all binding sites
(P,0.001). Genomic distribution of binding sites with or without a
p63 binding motif was similar to that of all binding sites (Figure S3). In
total, 10,895 genes had one or more p63 binding sites within 25 kb
up- and down-stream of the gene, and they were considered as
potential target genes (PTGs) of p63. GO annotation of these 10,895
PTGs using DAVID Bioinformatic Resources 6.7 (NIAID, NIH) [41]
showed a non-random distribution with enrichment in functional
categories of biological processes, such as development, adhesion, cell
communication and intracellular signaling cascade (Table S4).
Binding sites with or without a p63 motif were also mapped to genes
as separate subgroups, and 10,438 and 944 genes, respectively, have
p63 binding sites within 25 kb of the gene. GO annotation of genes
mapped by binding sites with motifs resulted in very similar GO
terms as annotation of all PTGs (Table S2). However, 944 genes
mapped by binding sites without motifs were seemingly involved in
slightly different biological processes (Table S4).
The p63 gene arose from two sequential gene duplications at the
root of the vertebrates and has unambiguous orthologues only in
that taxon [42]. We therefore assessed the evolutionary conserva-
tion of the identified binding sites and the p63 consensus motifs
therein in aligned vertebrate genomes (PhastCons). The identified
binding sites had higher average PhastCons Conservation Scores
(PCCS) and were significantly more conserved than random
sequences of the same size (Figure 2A). Moreover, PCCS of motifs
identified in the p63 binding sites were also compared to that in
the random genomic regions. By p63scan, 10,702 motifs were
identified in 11,369 p63 binding sites and they were more
conserved than 4,003 motifs identified in 100,000 random
genomic regions (Figure 2B). These data support the functionality
of the identified p63 binding sites. We did not observe a
correlation between PCCS and peak height (Figure S4A) or a
clear difference in PCCS of binding sites with and without p63
binding motifs (Figure S4B).
Association of potential p63 target genes with the
disease phenotypes
To validate whether the identified binding sites represented
target genes and regulatory elements relevant to the p63-associated
and other diseases with clinical similarities, the OMIM database
was searched for diseases associated with the 10,895 potential
target genes in this study. We found 904 OMIM disease entries
associated with these genes (Table 1, Table S5), referred to as p63
potential target gene-associated diseases (PTG-associated diseases).
To assess the relationship amongst PTG-associated diseases, their
clinical features were analysed by text mining (Table S6) and
evaluated with a similarity algorithm [43] (Table 1). The potential
target genes of p63 do not have strong tendency to associate with
diseases (P=1). However, the feature terms in PTG-associated
diseases are similar, as the similarity score of these diseases (0.284)
is significantly higher than for a random distribution (0.200)
(P,1E-6). This shows that PTGs are associated with diseases that
have similar clinical phenotypes. Features associated with p63
syndromes are enriched in the top 10% of overrepresented feature
terms for the PTG-associated syndromes (P,1E-28). Many of
these terms such as stem cell and epithelium reflect p63
functioning (Table S6). This suggests that identified PTGs tend
to cause similar disease phenotypes to p63-associated diseases. We
did not observe a significant difference between terms derived
from motif-containing binding sites or those from motif-less
binding sites (Table S6). The significant similarity of disease
features of PTGs suggests that these binding sites are relevant to
p63-related developmental disorders.
To assess whether p63 binding sites can function as regulatory
elements in the p63-related disease network, we focused on
SHFM. From the human malformation disease database POS-
SUM [44] and the Jackson Laboratory’s Mouse Genome
Database [45], 20 genes were selected based on their localization
in the human SHFM loci (Table S7). In addition, these genes are
known either to associate with SHFM in human or to have similar
phenotypes in mice. These genes are further referred to as SHFM-
Figure 2. Conservation of p63 binding sites and motifs in vertebrates. The percentage of p63 binding sites (y-axis) is plotted against
decreasing cut-off values of the PhastCons Conservation Score (PCCS) (x-axis). A point on the line indicates the percentage of binding sites with that
particular PCCS or higher. (A) Average PCS of 100-nucleotide regions centered at the summit of 11,425 p63 binding peaks (peaks 100) and that of
100,000 100nt regions randomly chosen from the whole genome (random 100). (B) Average PCCS of 10,659 10-nt p63 motifs detected by p63scan in
the 11,425 p63 binding peaks (peaks motifs) and of the 7,600 motifs detected in 100,000 random genomic regions (random motifs).
doi:10.1371/journal.pgen.1001065.g002
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associated genes (Table S7). As regulatory elements can function
over a large distance but might be blocked by insulator elements
that are defined by CTCF binding sites [46], p63 binding sites
were searched in broad chromosomal regions containing the
SHFM-associated genes (up to 300kb from the genes) provided
that no known CTCF binding sites are located between the
binding site and the gene. With these criteria, p63 binding sites
were identified near 12 SHFM-associated genes (Table 2). We
propose that these p63 binding sites are potential regulatory
elements that might contribute to SHFM.
Identification of p63 binding sites in a 7q21.3
microdeletion in an SHFM1 patient
In the SHFM1 locus on chromosome 7, several deletions have
been identified which invariably contain the DLX5 and DLX6
genes as well as DYNC1I1, SLC25A13 and DSS1 (Figure S5)
[28,47–51]. We identified a new patient with non-syndromic
SHFM (for clinical phenotype, see Materials and Methods) and a
novel microdeletion of chromosome 7q21 by a targeted 385K
chromosome 7-specific microarray. Surprisingly, the 880kb
chromosomal deletion at 7q21.3 encompassed DSS1, SLC25A13
and part of DYNC1I1 but left the SHFM1 candidate genes DLX5
and DLX6 intact (Figure 3). The deletion was confirmed by
genomic qPCR analysis (Figure S6). Compared with the
previously reported minimal chromosomal deletion (Figure S5)
[28,47–51], the protein-coding genes in the overlapping region are
DYNC1I1, SLC25A13 and DSS1 but these are not likely to
contribute to the phenotype [48,52,53]. We therefore hypothe-
sized that disruption of one or more regulatory elements caused
the SHFM1 phenotype. To test this hypothesis, p63 binding sites
were searched in the chromosomal region spanning the DLX5/
DLX6 genes, taking into account the published CTCF binding
sites to define the borders of enhancer activity [46]. Consistent
with our hypothesis that DLX5/DLX6 are controlled by long
distance regulatory elements, DLX5/DLX6 are located in a broad
chromosomal region between two CTCF binding sites (chr7:
95882240–95882467 and chr7: 96495007–96495206) spanning
approximately 600kb (green arrows in Figure 3). This region
contains nine putative p63 binding sites that were identified by
our ChIP-seq analysis. These include three high peaks (SHFM1-
BS1, -BS2 and -BS3) and six lower ones (a–f) (Figure 3, Table 3).
A p63 binding site within the SHFM1 deletion acts as an
enhancer element in limb development
To identify the binding sites potentially important for limb
development, the average PhastCons conservation score (PCCS)
[54] of each of the nine binding sites was examined. We found that
SHFM1-BS1 had the highest PCCS (0.456) (Table 3) that belongs
to the top-ranking 11.6% of all 11,369 binding sites (Figure 2 and
Figure S3). To test the functionality of p63 binding sites, the three
high p63 binding peaks, SHFM1-BS1, -BS2 and -BS3, were
cloned directly in front of a luciferase reporter that is followed by
the SV40 enhancer to test whether they are responsive to p63
transactivation. Transient transfection assays showed that only
SHFM1-BS1 was highly responsive to p63 (Figure 4A). Transacti-
vation activity was completely abolished by mutations in the p63
binding motif present in SHFM1-BS1 (Figure 4B, motif shown in
Figure 3), indicating that the observed transactivation is p63-
specific. Mutations in the DNA-binding domain of p63, R204W,
R279H and R304W, that are found in EEC syndrome disrupted
transactivation, whereas mutations found in non-syndromic
SHFM4, K194E, and in AEC syndrome, L517F, reduced the
transactivation activity not more than 2-fold (Figure 4C). Based on
Table 1. Diseases associated with genes containing p63
binding sites.
Diseases associated
with genes with
p63 binding sites
Total diseases in
OMIM associated
with genes P valueC
No. of diseases 904 2033 1
Similarity score
of feature termsA
0.284 0.200B ,1026
AText mined feature terms that are associated with diseases are calculated for
their similarity scores (0, no overlap and 1, identical overlap).
BRandomized sampling of 904 diseases from OMIM database are used for the
similarity score.
CChi-square test.
doi:10.1371/journal.pgen.1001065.t001
Table 2. p63-binding sites in the chromosomal regions near SHFM-associated genes (hg 18).
Gene Chr No. of peaks* Location of peaks
p63 chr3 4 191025109–191025933; 191034090–191035150; 191100798–191101709; 191150499–191151202
SNX3 chr6 3 108392374–108393394; 108590949–108591991; 108862963–108863753
GJA1 chr6 1 121848018–121848681
FOXP2 chr7 6 113725067–113725994; 113840901–113841821; 114182940–114183839; 114211827–114212755;
114250288–114251274; 114344204–114345050
DSS1 chr7 8 96029986–96030688; 96079266–96079792; 96110917–96111692; 96132694–96133405; 96177547–
96178220; 96194972–96195903; 96337204–96338894; 96388802–96389666
DLX6 chr7 3 96194972–96195903; 96337204–96338894; 96388802–96389666
DLX5 chr7 3 96194972–96195903; 96337204–96338894; 96388802–96389666
FBXW4 chr10 1 103514476–103515097
SMC3 chr10 4 112103092–112103960; 112147937–112149561; 112223542–112224445; 112243209–112244187
BRCA2 chr13 1 31904891–31905392
CDH3 chr16 2 67249490–67250527; 67259342–67260368
PORCN chrX 1 48204855–48205660
*Binding sites of p63 were searched within 300kb distance to the SHFM-associated genes and without CTCF binding sites in between.
doi:10.1371/journal.pgen.1001065.t002
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the structure of the DNA-binding domain in p53 that is highly
homologous to that in p63, lysine 194 (Q165 in p53) is located in
the DNA-binding domain but does not have direct contact with
DNA [5,55]. The AEC syndrome mutation L517F is located in the
SAM domain of p63. Therefore these mutations are unlikely to
have major effect on p63 DNA-binding. To examine the enhancer
activity of SHFM1-BS1, -BS2 and -BS3, these elements were
cloned in front of the SV40 promoter or endogenous mouse Dlx5
and Dlx6 promoters that drive the luciferase gene, but no clear
additional activation upon co-transfection of p63 was observed
(Figure 4D and 4E and data not shown). Furthermore, in the
absence of the enhancer, we did not detect p63 activation on the
Dlx5 promoter (Figure 4E, no BS) that was previously reported
[14]. This discrepancy is probably due to different cells used in
transient transfection assays. These results indicate that enhancer
activity controlling expression of DLX5 and DLX6 genes may not
be correctly recapitulated in a cellular system irrelevant to limb
development.
To understand gene expression controlled by enhancer
elements in embryonic limb development, we tested SHFM1-
BS1, -BS2 and -BS3 in a transgenic reporter assay in zebrafish. A
specific expression pattern of the GFP reporter controlled by
SHFM1-BS1 but not by SHFM1-BS2 and -BS3 (data not shown)
was observed in the AER and weakly in the ear and in the
forebrain (Figure 5A). Expression of p63 detected by in-situ
hybridization was only clearly localized to the AER (Figure 5B).
The reporter expression promoted by the SHFM1-BS1 in the
AER that directs growth and patterning of limbs and fins
correlated perfectly with the expression of p63, Dlx5 and Dlx6
during embryonic fin or limb development (Figure 5C) [14]. To
further determine whether gene expression regulated by SHFM1-
BS1 depends on p63 in zebrafish, we examined the enhancer
activity of SHFM1-BS1 in p63-knockdown embryos injected with
a specific p63 morpholino [4]. In p63-morphant embryos at
48 hours post fertilization (hpf), the fin buds were severely reduced
(mild) or absent (severe) (Figure 5C), as reported previously [3,4].
Figure 3. A microdeletion at SHFM1 locus on chromosome 7. A screenshot of UCSC genome browser shows the p63 binding profile from two
HKC cell lines (wt1 and wt2) with two p63 antibodies (4A4 and H129) near DLX5 and DLX6 on chromosome 7. SHFM1-BS1, -BS2 and -BS3 are three
high peaks and a–f are low ones. SHFM1-BS2 and -BS3 are in close proximity and therefore seen as a single peak in this large genomic view. Ultra-high
Comparative Genomic Hybridization array analysis performed with DNA of a SHFM1 patient showed a chromosomal deletion of 880 kb on
chromosome 7 (95,390,000–96,270,000, hg18, the orange arrow) which includes DSS1, SLC25A13 and part of DYNC1I1 but not DLX5 and DLX6.
Breakpoints and 20kb averaged log2 ratios were visualized in the genome browser. A previously reported minimal deletion determined by markers
D7S527 and D7S1796 [28] is marked with a black arrow. Binding sites identified in this ChIP-seq study and in previous ChIP-on-chip [17] are labeled in
red and black, respectively. CTCF binding sites revealed by previous ChIP-seq analysis [46] are labeled in green and two binding sites (chr7:
95,882,240–95,882,467 and 96,495,007–96,495,206) that define the enhancer activity of SHFM1-BS1 are marked by green arrows. A p63 consensus
binding motif was identified in SHFM1-BS1 with the essential cytosine and guanine bases labeled in red.
doi:10.1371/journal.pgen.1001065.g003
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In the mild phenotypes, the expression of GFP induced by the
enhancer was strongly reduced, as was the expression of the zdlx5a
and zdlx6a genes. No fin defects were observed in embryos injected
with a control morpholino (data not shown). Enhancer activity of
SHFM1-BS1 was also tested in transgenic reporter assays in mice.
Consistent with the zebrafish data, specific expression was
observed in the AER in mouse embryos (E9.5 and E15), and the
expression was lost when the p63-binding motif was mutated in
SHFM1-BS1 (Figure 5D). These data showed that the specific
expression in AER is dependent on p63. Taken together, our data
obtained from animal models clearly demonstrated that SHFM1-
BS1 can function as an enhancer element to control gene
expression during embryogenesis and its activity is dependent on
p63.
Having shown that gene expression regulated by SHFM1-BS1
correlates with that of Dlx5 and Dlx6 in zebrafish and mice, we
tested whether SHFM1-BS1 physically interacts with the Dlx5 and
Dlx6 promoters. To do that, we used the Chromosome
Conformation Capture technique (3C) [56] that allows detecting
the three-dimensional proximity of two chromosomal locations
(Figure 5E and 5F and Figure S7). In mouse embryonic limb
tissues (E10), the interaction frequencies of SHFM1-BS1 with the
promoter of Dlx6 and with the intergenic region between Dlx5 and
Dlx6 were clearly higher than with the surrounding regions. This
indicates that SHFM1-BS1 indeed strongly interacts with Dlx6. A
weaker interaction of SHFM1-BS1 with Dlx6 was also detectable
in E15 limbs. In addition, SHFM1-BS1 appeared to interact with
the intergenic region between Dlx5 and Dlx6 that contains highly
conserved enhancer elements [57,58]. We did not observe clear
interaction of SHFM1-BS1 with the promoter of Dlx5. Taken
together, our data show that p63 binding sites identified in HKCs
can function as regulatory elements to control gene expression in
embryonic limb development. We further conclude that disruption
of regulation of DLX5 and DLX6 controlled by p63 likely causes
SHFM1.
Discussion
In this study, we established the DNA-binding profiles of p63 in
a physiologically relevant human cellular system to identify target
genes and regulatory elements controlled by p63. We show that
one of the identified p63 binding sites acts as a cis-regulatory
element to control gene expression in the AER that correlates
perfectly with the expression pattern of DLX6 and DLX5 during
embryonic development. A novel microdeletion that includes this
binding site but leaves DLX5 and DLX6 intact leads to SHFM.
With a prevalence of 2–6% in humans, congenital malforma-
tions represent a major medical problem [59]. Elucidation of the
genetic basis of this heterogeneous group of disorders is important
for genetic counseling and for basic research. Although current
main stream genetic studies still focus on mutations in the coding
regions of genes, disease mechanisms associated with genetic
variants in short- or long-range regulatory elements are increas-
ingly recognized. Consistent with regulatory elements being
required for correct spatio-temporal expression of developmental
genes [60], mutations in non-coding cis-regulatory elements have
been reported to cause congenital defects and have emerged as a
disease mechanism [61–64]. Evolutionary conservation can be a
powerful tool in the identification of regulatory elements [65–67].
A recent study identified a number of highly-conserved elements
surrounding the IRF6 gene which is known to be involved in
several types of syndromic and non-syndromic cleft lip/palate
[68]. In one of these elements a SNP that affects an AP-2alpha
binding site was identified to associate with increased risk of cleft
lip. This conserved element was able to drive the expression of a
reporter gene during mouse orofacial development. Interestingly,
in our ChIP-seq study we identified the very same cis-regulatory
element as a strong p63 binding site that functions as an enhancer
element to control expression of IRF6 [69]. However, as only
ultra-conserved elements are the focus of the evolutionary
conservation approach, not all important regulatory elements
can be identified. For example, conservation analysis in verte-
brates of the enhancer element SHFM1-BS1 in our study was not
found as an ultra-conserved element (Figure S8 and data not
shown), even though it is well conserved. In addition, the identity
of the transcription factors controlling regulatory elements may
not always be derived from the genomic sequences. Our functional
strategy of genome-wide p63 binding profiling does not depend on
motif prediction or evolutionary conservation and reveals a large
number of potential cis-regulatory elements controlled by p63.
We used human keratinocytes for our studies as recent work on
transcription factor p53 revealed that responsive elements are not
always conserved across species [70]. Moreover, primary HKC
cell lines represent a cell type that is highly significant for p63-
associated disorders. As many as 43% of the binding sites (2510
out of 5807) from a p63 binding dataset using the ChIP-on-chip
technique in a cervical carcinoma cell line [17] were also present
in our ChIP-seq dataset. Given that different cell types and
techniques were used in these studies, the overlap of these two
datasets is remarkable. Nevertheless, our data from HKCs are
highly reliable (Figure S1, Table S1) and appear to represent
functional p63 binding sites more accurately [17].
Similar to recent reports on DNA-binding profiles of other
gene-specific transcription factors [71–74], the number of
identified p63 binding sites is large, which was not predicted by
the classical paradigm of gene transactivation. Our extensive
bioinformatic analyses suggest that the majority of the identified
p63 binding sites are biologically functional, as 94% of the binding
sites contain a p63 consensus motif, and evolutionary conservation
(Figure 2) and phenotypic similarity of PTG-associated diseases
(Table 2) are significantly higher than random expectation. The
binding sites are frequently located in intronic regions or at a
distance from promoters. Thus gene-specific transcription factors
may not only activate transcription at proximal promoters but also
regulate gene expression at a distance perhaps by looping
mechanisms. A recent report on the chromatin interaction map
of the Oestrogen-Receptor-a (ERa) [75] also found long-range
interaction of ERa binding sites and their target genes. This
Table 3. PhastCons Conservation Scores (PCCS) of the
identified p63 binding sites that potentially function as
enhancer elements.
binding sites start end PCCS*
a 96030294 96030493 0.434
b 96079364 96079563 0.234
c 96111217 96111416 0.041
d 96133015 96133214 0.010
e 96177897 96178096 0.043
BS1 96195551 96195750 0.456
BS2/BS3 96337526 96337725 0.002
f 96389201 96389400 0.088
*Average PhastCons Conservation Score of the binding sites (hg18).
doi:10.1371/journal.pgen.1001065.t003
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proposed looping mechanism is consistent with the notion that
SHFM1-BS1 physically interacts with the DLX5/DLX6 genes that
are located more than 250kb downstream from SHFM1-BS1
(Figure 5E and 5F). Furthermore, binding sites identified in a
certain cell type may also represent target genes and regulatory
elements that can be regulated at different developmental stages in
other cells and tissues. For example, SHFM1-BS1 was identified in
human adult skin keratinocytes where DLX5/DLX6 are moder-
ately expressed and their expression is not altered in EEC patient
keratinocytes (our unpublished data). Nevertheless, SHFM1-BS1
can drive gene expression in the AER during early embryonic limb
development.
It has been well established that p63 plays an important role in
limb development, as mutations in p63 give rise to limb defects in
complex syndromes as well as to isolated SHFM (SHFM4) [21]. In
this report, our data strongly indicate that p63 plays a role in
SHFM1 by regulating DLX5/DLX6 through SHFM1-BS1 that
physically interacts with the Dlx6 promoter in the AER (Figure 5F).
DLX5 and DLX6 were previously reported as target genes of p63
as p63 binds to Dlx5/Dlx6 promoters and activates these genes
Figure 4. Transient transfection analysis of p63 binding sites at SHFM1 locus on chromosome 7. (A) The p63 binding sites SHFM1-BS1, -
BS2 and -BS3 were tested in transient transfection assays in Saos2 cells. Transcription of the luciferase reporter was strongly activated by DNp63a
through SHFM1-BS1 binding site but only weakly activated through -BS2 and -BS3. (B) Activation was abolished when point mutations were
introduced into the p63 binding motif in the SHFM1-BS1 binding site where the essential cytosine and guanine bases were mutated to adenosines.
(C) Activation was impaired by p63 EEC mutations R204W, R279H and R304W and slightly reduced by SHFM1 mutation K194E and AEC mutation
L517F. (D) No additional activation was observed when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the SV40 promoter driving luciferase. (E) No
activation was observed on the mouse Dlx5 promoter (no BS) and when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the Dlx5 promoter.
doi:10.1371/journal.pgen.1001065.g004
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Figure 5. Functional analysis of SHFM1-BS1 to control gene expression in zebrafish and mice. (A) SHFM1-BS1 was cloned in a reporter
construct carrying GFP. Expression of the GFP gene in zebrafish showed that SHFM1-BS1 can control gene expression at the apical ectodermal ridge
(AER), the ear and the forebrain. The red fluorescence expressed in the muscles in the first zebrafish panel corresponds to the positive control of
transgenesis. (B) Expression of zp63 in the AER was detected by in situ hybridization. (C) Expression patterns of transgene GFP controlled by SHFM1-
BS1, zdlx5a and zdlx6a were analysed by in situ hybridization in 48hpf zebrafish embryos. The same specific expression of these genes was observed
in the AER. Treatment of p63 morpholino in zebrafish embryos resulted in mild (reduced fins) and severe (no fins) phenotypes. Accordingly, the
expression of GFP, zdlx5a and zdlx6a is either reduced or absent in p63 morphant embryos. (D) SHFM1-BS1 was cloned in a reporter construct
carrying the LacZ gene to generate transgenic mice. Specific expression of LacZ in the AER was shown at E9.5 and E15. Mutations in the p63 binding
motif in SHFM1-BS1 disrupted the specific expression pattern in mice (E15). (E) A diagram shows chromosomal locations of SHFM1-BS1 and Dlx5/Dlx6.
PCR primers used in the 3C experiment are indicated. (F) Three-dimensional physical interaction of SHFM1-BS1 to Dlx5/Dlx6 was analysed by
Chromosome Conformation Capture (3C) technique in mouse embryonic limb tissues (E10 and E15). SHFM1-BS1 interacts strongly to the Dlx6 gene,
as interaction frequency was clearly higher at the Dlx6 gene than at surrounding regions. Interaction frequency is expected to attenuate over distance
to SHFM1-BS1 if there is no active interaction. Error bars represent standard errors (N = 8 or 11 for E10 or E15 limbs, respectively).
doi:10.1371/journal.pgen.1001065.g005
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[14]. However, we did not detect p63 binding sites at the promoter
regions of these two genes in our HKCs (Figure 3). It is plausible
that looping of SHFM1-BS1 to the promoters may result in a
binding signal in a ChIP experiment. We also did not observe p63
activation on the Dlx5/Dlx6 promoters in transient transfection
assays (Figure 4E and data not shown). In addition, the SHFM4
mutations only affected transactivation mediated by SHFM1-BS1
moderately in our transfection assay using Saos2 cells which do not
express any endogenous p53 and p63 (Figure 4C). The disruption
of activation on Dlx5/Dlx6 promoter was previously reported in
transfection assays using U2OS cells where endogenous wild type
p53 is expressed [14]. The use of different cells in transfection
assays may be responsible for the variable results of transactivation
assays. Moreover, our observations suggest that SHFM4 mutations
that do not directly affect DNA-binding might disrupt protein-
protein interaction or DNA looping to the Dlx5/Dlx6 promoters to
abolish transactivation. Importantly, we showed that the enhancer
element SHFM1-BS1 activates gene expression in the AER during
embryogenesis and that this activation is p63 dependent.
In addition to the functional data in model systems, we provide
genetic data that support an important role for the enhancer
element SHFM1-BS1 in limb development by the identification of
a novel microdeletion 7q21 in an SHFM patient. This is a unique
microdeletion, as the reported deletions in the SHFM1 patients so
far all contain SHFM1-BS1 and DLX5/DLX6 (Figure S5)
[22,28,47–51,76–81]. Within the novel deletion, DYNC1I1 and
SLC25A13 are unlikely to play a role in limb development [52,53].
The other gene within the minimal deletion is DSS1. DSS1 is
expressed in the mesenchyme of the developing mouse limb [48],
and the causative role of DSS1 in SHFM1 has not been
demonstrated. Moreover, the expression of DSS1 in limb bud
mesenchyme remains normal in DLX5/DLX62/2 mice displaying
typical SHFM phenotypes [34]. Our functional analyses support
the notion that the enhancer element SHFM1-BS1 regulates
expression of DLX6 and possibly DLX5, and that loss of this gene
regulation gives rise to SHFM1. This model is in agreement with
recent reports on genomic aberrations in 7q21 that were
associated with SHFM1. In one report, a human breakpoint
located at 38 kb telomeric to DSS1 and at 258 kb centromeric to
DLX6 is associated with SHFM and hearing loss phenotype
(Figure S5) [82]. This breakpoint leaves the SHFM1-BS1
association with DSS1 intact, but disconnects it from DLX5 and
DLX6. Interestingly in this translocation, the chromosomal context
between the p63 binding sites SHFM1-BS2 and -BS3 with DLX5/
DLX6 is not affected, which suggests that SHFM1-BS2 and -BS3
do not play a role in SHFM1. Another report identified a familial
paracentric inversion-deletion 7q21 that affected a potential
enhancer element (Figure S5) [83]. However, the spatio-temporal
expression mediated by the identified element in this report did
not support a role in limb development. Therefore, it is more likely
that the SHFM phenotype in this family is due to the dissociation
of the DLX5/DLX6 genes from SHFM1-BS1 by the inversion. It
should be noted that in the same report, a 5,115 bp deletion
(chr7:96,402,577–96,407,691, hg18) was identified at the break-
point. We did not observe a p63 binding site in this deletion
(Figure 5S). Our results and those from others thus support the
hypothesis that SHFM1-BS1 plays an essential role in the
regulation of DLX5/DLX6. A genetic approach to delete
SHFM1-BS1 in mice can give an unambiguous demonstration
of its role to control expression of Dlx5 and Dlx6. Intriguingly,
whereas Dlx5/Dlx6 are expressed in the craniofacial region at later
stages of development (E14–17 in mice) [29,34], absence of
specific expression controlled by SHFM1-BS1 in craniofacial
regions indicates that SHFM1-BS1 is not a regulatory element for
orofacial development (data not shown). Different enhancer
elements may regulate DLX5 and DLX6 in these tissues. It will
be of interest to test other less conserved p63 binding sites within
the CTCF boundaries for a role in craniofacial development.
In summary, we have identified binding sites of p63 and taken
the first step to build a gene network regulated by p63 with ChIP-
seq analysis in human primary keratinocytes. Our study provides
potential target genes as well as high-resolution regulatory
elements relevant to p63-related diseases. Reporter assays in a
large scale to test p63 binding sites in the animal models will
provide valuable information on functions of p63 target genes in
ectodermal development. Our findings strongly indicate that loss
of the regulatory element SHFM1-BS1 identified by a p63 binding
site constitutes a novel disease mechanism responsible for SHFM1.
Identified target genes and regulatory elements of p63 can
therefore be analysed for mutations and microdeletions to
understand the disease mechanisms of unresolved diseases that
resemble p63-associated syndromes.
Materials and Methods
Ethics statement
All procedures regarding establishing human primary keratino-
cytes were approved by the ethical committee of the Radboud
University Nijmegen Medical Centre (‘‘Commissie Mensgebonden
Onderzoek Arnhem-Nijmegen’’). Informed consent was obtained.
All animal work has been conducted according to relevant
national and international guidelines.
Clinical summary of the SHFM1 patient
The patient was born with bilateral foot anomalies and had no
other dysmorphic features, in particular no hand anomalies,
evidence of ectodermal dysplasia, scalp defects, oral cleft, bifid
uvula, tear duct anomalies, eyelid adhesions or abnormal nails. On
review at age 2 years and 7 months of age, she was healthy and
was well grown and development was within normal limits.
Human primary keratinocyte culture
Skin biopsies were taken from the trunk of healthy volunteers to
set up the primary keratinocyte culture [84]. Keratinocyte cultures
in Keratinocyte Growth Medium (KGM) under undifferentiated
condition were previously described [85].
ChIP and ChIP–seq
Human primary keratinocytes under proliferating condition
where p63 is expressed at the highest level were used for ChIP and
ChIP-seq analysis. Cells were crosslinked with 1% formaldehyde
for 10 minutes and chromatin was collected as described [86].
Chromatin was sonicated using a Bioruptor sonicator (Diagenode)
for 2 times of 8 minutes at high power, 30s ON, 30s OFF. p63
antibodies 4A4 (Abcam) and H129 (Santa Cruz) were used in
ChIP-qPCR and ChIP-seq analyses. ChIP experiments were
performed as previously described [37]. ChIP-seq analysis was
performed on a Solexa Genome Analyzer (Illumina) as described
previously [71].
ChIP-seq data analysis
All 32-bp sequence reads were uniquely mapped to the human
genome NCBI build 36.1 (hg18) with zero or one mismatch using
ELAND (Illumina), resulting in 3.2, 6 and 20 million unique reads
for the three analyzed samples, wt1 with 4A4 ChIP, wt2 with 4A4
ChIP and wt2 with H129 ChIP, respectively. Peak recognition was
performed using MACS [35] with default settings and a P value
threshold of 1E-9, giving 18,133, 14,963 and 29,166 peaks in
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ChIP-seq tracks of wt1 with 4A4 ChIP, wt2 with 4A4 ChIP and
wt2 with H129 ChIP, respectively. Peaks were mapped to RefSeq
genes, downloaded from the UCSC Genome Browser (hg18), to
determine genomic location. The ChIP-seq data and associated
peaks have been deposited in NCBI’s Gene Expression Omnibus
[87] and are accessible through GEO Series accession number
GSE17611 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc
=GSE17611).
De novo motif search
To determine the p63 motif, a de novo motif prediction pipeline
combining three motif prediction tools, MotifSampler [88],
Weeder [89] and MDmodule [90], was run on 2273 (20%)
randomly selected 200-bp peak sequences (centered at the peak
summit as reported by MACS) and PWMs were generated. We
used the ‘large’ analysis setting for Weeder. MDmodule and
MotifSampler were each used to predict 10 motifs for each of the
widths between 6 and 20. The significance of the predicted motifs
was determined by scanning the remaining 80% of the peak
sequences and two different backgrounds: a set of random
genomic sequences with a similar genomic distribution as the
peak sequences and a set of random sequences generated
according to a 1st order Markov model, matching the dinucleotide
frequency of the peak sequences. P values were calculated using
the hypergeometric distribution with the Benjamin-Hochberg
multiple testing correction. All motifs with a P value,0.001 and
an absolute enrichment of at least .1.5-fold compared to both
backgrounds were determined as significant. We calculated the
ROC AUC for all significant motifs and chose the best performing
motif based on the ROC AUC (See Table S2 for the results). The
PWM of this motif was combined with the p53scan algorithm to
generate p63scan, using an optimal threshold, determined by the
maximum f-measure as described previously [37]. The p63scan
algorithm can be downloaded from http://www.ncmls.eu/
bioinfo/p63scan/. To examine the correlation of motif score
and peak height, all peaks were divided in quartiles according to
peak height (the number of reads per peak). For each quartile the
distribution of the motifs score as determined by p63scan is
depicted as a boxplot.
Motif over-representation analysis using TRANSFAC
To detect putative transcription factor motifs reported in the
TRANSFAC Professional database version 2009.3 [39], the
MotifScanner program [91] was used. The search was performed
on both strands using a 3rd-order Markov model calculated from
the human promoter set of the Eukaryotic Promoter Database
(EPD) as a background model. The parameter p (a prior
probability of finding one instance of the motif in a sequence)
was set to a value of 0.5. To identify motifs that are
overrepresented in the p63 motif-less binding sites, the binomial
test was used. The obtained P values were corrected for multiple
testing (631 motifs for which sites were found in the p63-binding
regions) using a Bonferroni correction.
Quantitative PCR
Quantitative PCR primers were designed using Primer3
(http://frodo.wi.mit.edu) [92], and qPCR reactions were per-
formed in the 7500 Fast Real Time PCR System apparatus
(Applied Biosystems) by using iQ SYBR Green Supermix (Biorad)
according to the manufacturer’s protocol. For qPCR of ChIP
analysis, one primer set was used for each tested binding region
(Table S8) and ChIP efficiency of certain binding sites was
calculated using percentage of ChIPped DNA against input
chromatin.
Analysis of potential target genes associated with
phenotypic defects using human and mouse disease
bases
Text mining-based [43] feature overrepresentation and gene to
disease mapping were determined using the Online Mendelian
Inheritance in Man (OMIM) disease database [93,94]. Detailed
information can be found in supplementary information. Human
diseases associated with SHFM were taken from the Pictures Of
Standard Syndromes and Undiagnosed Malformations (POS-
SUM) database [44], current as of August 2007, and mapped to
genes through their OMIM IDs. Mouse SHFM-associated
phenotypes and associated genes were taken from the Jackson
Laboratory’s Mouse Genome Database (http://www.informatics.
jax.org/) [45].
Evolutionary conservation of binding sites
To assess the evolutionary conservation of the 11,369 sites
bound by p63, the PhastCons [54] conservation track from the
UCSC Genome Browser was used to calculate PhastCons
Conservation Score (PCCS). Conservation based on 44 vertebrate
genomes was chosen because the p63 gene has 1-1 orthologs
throughout the vertebrates [42]. The conservation for a region was
calculated as the average conservation of each nucleotide therein.
To analyse the correlation of PCCS and peak height, all peaks
were divided in quartiles according to peak height (the number of
reads per peak). For each quartile the distribution of the
PhastCons Conservation Scores (PCCS) is depicted as a boxplot.
Mapping deletion in a SHFM patient using ultra-high
comparative genomic hybridization
For detailed detection of chromosome 7 aberration, high
resolution NimbleGen HG18 chromosome 7 specific 385K arrays
were used (B3738001-00-01; Roche NimbleGen Systems, Madi-
son, Wisconsin, USA). The 385K average probe distance was
365bp. DNA labeling, array hybridization, post-hybridization
washes and scanning were performed according to the manufac-
turer’s instructions (Roche NimbleGen). The acquired images
were analyzed using NimbleScan V2.4 extraction software (Roche
NimbleGen). For each spot on the array, the log2 Cy3/Cy5 ratio
(relative intensity of the Cy3 labeled patient DNA vs. the Cy5
labeled male DNA reference pool of 5 healthy male individuals)
was calculated using the segMNT algorithm, which also applied
an automatic segment detection. A 506 averaging window was
generated, resulting in 20kb segments for this array. Breakpoints
were determined with SignalMap V1.9 software (Roche Nimble-
Gen) and 20kb averaged log2 ratios were visualized in the UCSC
genome browser.
Constructs and transactivation assays
The genomic regions of p63 binding site peaks were amplified
by PCR with gateway cloning primers and cloned into a modified
ccdB-containing pGL3-Enhancer Vector, or a ccdB-containing
pGL3-Promoter Vector, or a ccdB-containing pGL3-Dlx5 Vector.
The ccdB-containing pGL3-Dlx5 Vector was generated by
amplification of mouse genomic DNA using primers described
in Table S8 to obtain the mouse Dlx5 promoter to replace the
SV40 promoter with BglII and HindIII sites in the ccdB-containing
pGL3-Promoter Vector. Point mutations were introduced into
p63-binding motifs of SHFM1-BS1 to generate mutant p63
binding sites, where the essential cytosine and guanine bases were
mutated to adenosine. The DNp63a wild-type (pcDNA-
mM_DNp63a) expression plasmid has been described previously
[85]. Point mutations were introduced into this plasmid to
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generate R204W, R279H, R304W, K194E and L517F mutations.
Transfection and luciferase assays were described previously [85].
All cloning and mutagenesis primers are described in Table S8.
Transgenic reporter analyses in zebrafish and mice
Human genomic fragments containing the SHFM1-BS1, -BS2
and -BS3 were amplified with primers described in Table S8. The
PCR fragments were subcloned in PCR8/GW/TOPO vector and
then transferred, through recombination using Gateway technol-
ogy, to the ZED destination vector for zebrafish transgenesis [95].
This vector contains the Xenopus Cardiac actin promoter driving
DsRed as a positive control for transgenesis. To generate the
zebrafish transgenic embryos, we used Tol2 transposon/transpos-
ase method [96] with minor modifications. Volume of 2–5nl of
mixture containing 25ng/ul of transposase mRNA, 20ng/ul of
phenol/chloroform purified ZED constructs and 0.05% phenol
red was injected in the cell of 1 cell stage embryos. Three or more
independent stable transgenic lines were generated for each
construct. For the generation of transgenic mice, the genomic
fragments with and without point mutations in p63 consensus
motif were transferred into a vector containing the human
minimal beta-globin promoter, lacZ and a SV40 polyadenylation
signal. Constructs were linearized and the vector backbone
removed prior to microinjection into the pronucleus of one-cell
mouse embryos. F0 embryos of 9.5–13 dpc stages were harvested
and stained for lacZ activity.
Morpholino injections and in situ hybridizations in
zebrafish embryos
Once cell stage embryos were injected with 3ng of DNp63 MO
II (TCCACAGGCTCCAGGATTCTTACCC) as described pre-
viously [4]. Injected embryos were raised at 28uC in standard E3
medium and fixed at 48 hours post fertilization in 4% parafor-
maldehyde overnight at 4uC. In situ hybridizations were carried
out as described [97]. As a control, we injected a similar amount of
a MO directed against the Xenopus tropicalis olig2 gene that shows no
match in the zebrafish genome [98].
Chromosome Conformation Capture (3C) assay
Chromosome Conformation Capture (3C) assay was per-
formed as referred in Hagege et al., 2007 [56]. Limbs of E10- and
E15-stage mouse embryos were dissected and processed to get
single cells preparations. Ten million isolated cells were first
fixated with 2% formaldehyde, and then cells were lysed and
nuclei were digested with HindIII endonuclease (Roche). After
that, DNA was ligated with T4 DNA ligase (Promega) in low
concentration conditions to favour intramolecular ligations. A set
of locus specific primers close to a HindIII site (Table S8) was
designed with Primer3 v. 0.4.0 [92]. These primers were used to
make semi-quantitative PCRs to measure the relative enrichment
in each ligation product. The primer near to the BS1 enhancer
was taken as the fixed primer, and the different interactions were
tested using primers close to the promoters of DLX5 and DLX6
genes. For each interaction two negative control primers were
designed about 30 kb upstream and downstream the promoter
specific primer. PCR products were run in agarose gels and
measured using a Typhoon scanner. Product values were related
to a control composed of two BACs that encompass our region of
interest.
Supporting Information
Figure S1 ChIP-qPCR analysis of p63 binding in human
primary keratinocytes using two different p63 antibodies 4A4
(pan-p63) and H129 (a-specific). Specific binding of p63 to the
tested binding sites was observed, including to binding sites at
p21WAF/CIP19 and DST which served as positive controls, but not
to the negative controls myoglobin exon 2 (myo) and a no-gene
region (chr11).
Found at: doi:10.1371/journal.pgen.1001065.s001 (0.16 MB PDF)
Figure S2 Correlation of motif scores to peak heights. All peaks
were divided in quartiles according to peak height (the number of
reads per peak). For each quartile the distribution of the motifs
score as determined by p63scan is depicted as a boxplot.
Found at: doi:10.1371/journal.pgen.1001065.s002 (0.16 MB PDF)
Figure S3 Genomic distribution of p63 binding sites with and
without p63 consensus binding motifs.
Found at: doi:10.1371/journal.pgen.1001065.s003 (0.13 MB PDF)
Figure S4 Correlation of PhastCons Conservation Scores
(PCCS) to peak heights and p63 binding motifs of the p63 binding
sites. (A) The percentage of p63 binding sites (y-axis) is plotted
against decreasing cut-off values of the PhastCons Conservation
Score (PCCS) (x-axis) for two groups of peaks: those with a p63
motif and those without a p63 motif, as determined by p63scan.
(B) All peaks were divided in quartiles according to peak height
(the number of reads per peak). For each quartile the distribution
of the PhastCons Conservation Scores (PCCS) is depicted as a
boxplot.
Found at: doi:10.1371/journal.pgen.1001065.s004 (0.08 MB PDF)
Figure S5 Previously reported chr.7 deletions involved in
SHFM1 (hg18). (A) The grey track CGH array CNV data with
deletion in the SHFM1 patient is compared to the minimum
critical regions for SHFM1 based on the literature. Pale green
tracks represent deleted intervals in patients with SHFM1 who
have cytogenetic deletions (Del Porto et al., 1983; Tajara et al.,
1989; Morey et al., 1990; Roberts et al., 1991; Nunes et al., 1994;
McElveen et al., 1995; Montgomery et al., 2000). Dark green tracks
represent deleted intervals in patients with SHFM1 where
mapping has been done with STS markers (Marinoni et al.,
1995; Crackower et al., 1996; Fukushima et al., 2003; Wieland et al.,
2004). Purple tracks represent summed mapping of deletions
combined from many patients with SHFM1 (Scherer et al., 1994;
Tackels-Horne et al., 2001). The brown track represent a
microdeletion at the break point of a chromosome inversion in a
patient with SHFM1 (Brown et al., 2010). The red bar represents
three p63 binding sites. (B) A zoomed-in view of the region
including SHFM1-BS1, -BS2 and -BS3 and DLX5/6. A
translocation in SHFM1 that disconnects SHFM1-BS1 with
DLX5/6 is depicted with a black arrow (Saitu et al., 2009).
Found at: doi:10.1371/journal.pgen.1001065.s005 (0.24 MB PDF)
Figure S6 Genomic qPCR analysis of deletion of the p63
binding site SHFM1-BS1 in the SHFM1 patient. Genomic qPCR
was performed to confirm the deletion in the SHFM1 patient
revealed by CGH analysis. Copy number was calculated against
an internal control primer set in the CFTR gene.
Found at: doi:10.1371/journal.pgen.1001065.s006 (0.18 MB PDF)
Figure S7 Raw data of 3C experiments in mouse limbs at E10
and E15.
Found at: doi:10.1371/journal.pgen.1001065.s007 (0.47 MB PDF)
Figure S8 Evolutionary conservation of the p63 binding site
SHFM1-BS1 in vertebrates. SHFM1-BS1 was examined for its
conservation in vertebrates using USCS genome browser. The
consensus motif of p63 is highlighted in the red box.
Found at: doi:10.1371/journal.pgen.1001065.s008 (0.19 MB PDF)
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Table S1 Validation by ChIP-qPCR of detected binding sites in
ChIP-seq analysis.
Found at: doi:10.1371/journal.pgen.1001065.s009 (0.07 MB
DOC)
Table S2 Motif analysis with a de novo motif prediction pipeline.
Found at: doi:10.1371/journal.pgen.1001065.s010 (0.02 MB
XLS)
Table S3 The motifs significantly overrepresented in the p63
motif-less binding sites.
Found at: doi:10.1371/journal.pgen.1001065.s011 (0.03 MB
DOC)
Table S4 The most significant GO annotation terms of potential
target genes of p63.
Found at: doi:10.1371/journal.pgen.1001065.s012 (0.05 MB
DOC)
Table S5 OMIM IDs associated with genes containing p63
binding sites.
Found at: doi:10.1371/journal.pgen.1001065.s013 (0.14 MB
XLS)
Table S6 Affected features in p63 potential target gene-
associated diseases (PTG-associated diseases).
Found at: doi:10.1371/journal.pgen.1001065.s014 (0.37 MB
XLS)
Table S7 Genes potentially involved in SHFM mouse models or
human SHFM phenotypes.
Found at: doi:10.1371/journal.pgen.1001065.s015 (0.04 MB
DOC)
Table S8 Primers for expression, ChIP analyses, and for cloning.
Found at: doi:10.1371/journal.pgen.1001065.s016 (0.03 MB
XLS)
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